CP-START-001 CP-START-001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Me

NCT05592626

CP-START-001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

Associated Conditions

Metastatic Solid Tumors

Principal Investigator

Guru Sonpavde

Sponsor

Marengo Therapeutics, Inc

The purpose of this research study is
To test the safety of study drug STAR0602. To see how well different doses of the study drug STAR0602 are tolerated in different groups of patients. To understand how the body absorbs and processes different doses of the study drug STAR0602. The is known as pharmacokinetics (PK). To understand the effect of the study drug on cells of the body and which patients might respond to study drug STAR0602. This is known as pharmacodynamics (PD). Assess the preliminary anti-tumor activity of the study drug as the only therapy used in subjects with advanced solid tumors.

This study is currently enrolling.